Health Canada approved Boey (trenibotulinumtoxinE) for moderate-to-severe frown lines in adults on June 23, and the detail that matters is the molecule: this is the first market authorization anywhere for a botulinum neurotoxin built on serotype E, the class every product you currently use (serotype A) is not. The pitch is a different shape of result. Boey has a rapid onset, with some patients seeing effect as early as 8 hours after injection, and a deliberately short duration, with effects wearing off in roughly two to three weeks.

That short window is the point, not a limitation. Two Phase 3 trials (M21-500 and M21-508) enrolled 947 patients, with Day 7 composite responder rates of 60.0% and 65.7%. A toxin that fully resolves in a few weeks reads as a trial product: a patient who has never touched neurotoxin and wants to see what frown-line softening looks like before committing to a standard three-to-four-month treatment.

For US practices this is a heads-up, not an order form. The FDA issued a Complete Response Letter in April 2026 over manufacturing rather than safety or efficacy, which is why Canada is the first green light while review continues in several other countries. Worth tracking how the short-acting category lands north of the border, since it is the kind of pipeline shift that reshapes how first-time patients get introduced to injectables.

Source: AbbVie / Allergan Aesthetics (newsroom) — https://news.abbvie.com/2026-06-23-Allergan-Aesthetics-receives-approval-for-Boey-R-trenibotulinumtoxinE-in-Canada,-the-first-and-only-rapid-onset,-short-duration-neurotoxin-for-the-temporary-improvement-of-frown-lines-in-adult-patients